Clinical trials recruiting for Lung Neuroendocrine Neoplasm
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Everolimus | 2 |
| 177Lu-edotreotide | 1 |
| Cabozantinib and Temozolomide | 1 |
| Lutetium Lu 177 Dotatate | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Alabama | 1 |
| California | 1 |
| District of Columbia | 1 |
| Florida | 1 |
| Illinois | 1 |
| Iowa | 1 |
| Massachusetts | 1 |
| Minnesota | 1 |
| Missouri | 1 |
| North Carolina | 1 |
| Ohio | 1 |
| Pennsylvania | 1 |
Top cities
Self-screener
Recruiting trials
- A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
- Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Related conditions
Trials recruiting for Lung Neuroendocrine Neoplasm often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Lung Neuroendocrine Neoplasm trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.